Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Debra Brown

Nurse Practitioner Warsaw, NY Nurse Practitioner

NPI 1932107885 CMS profile 10674467

34 Duncan St, Warsaw, NY 14569

Open in the dashboard

General payments

$2,679

155 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Debra Brown of Warsaw, NY is reported in the CMS Open Payments database as having received $2,679 across 155 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $482 26
2022 General $1,068 56
2021 General $1,130 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Debra Brown
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Debra Brown were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Debra Brown Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,130 $135 $40–$426 $132
2022 $1,068 $152 $48–$470 $149
2023 $482 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Novo Nordisk Inc $673 43 payments
  2. Pfizer Inc. $315 23 payments
  3. AstraZeneca Pharmaceuticals LP $308 14 payments
  4. Astellas Pharma US Inc $212 9 payments
  5. GlaxoSmithKline, LLC. $165 9 payments
  6. Abbott Laboratories $148 7 payments
  7. Lilly USA, LLC $98 6 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $93 6 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $91 5 payments
  10. Amgen Inc. $66 4 payments
  11. Other $510 29 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $2,499 153 payments
  2. Education $180 2 payments
Products named General payments · program years 2021–2023
  1. Ozempic $592 39 payments
  2. RYBELSUS $586 38 payments
  3. ELIQUIS $257 18 payments
  4. COLOGUARD DNA CAPTURE REAGENTS $253 18 payments
  5. FARXIGA $244 10 payments
  6. TRELEGY ELLIPTA $165 9 payments
  7. BREZTRI $161 4 payments
  8. LOKELMA $122 3 payments
  9. FreeStyle Libre 2 $99 5 payments
  10. XIFAXAN $93 6 payments
  11. Other $1,246 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 176 drugs

Part D claims

11,031

Median for Nurse Practitioner: 389

Drug cost

$1,175,527

Median for Nurse Practitioner: $21,885

Branded share of claims

22.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 207 $223,861
Eliquis Apixaban Brand 181 $167,345
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 96 $90,218
Jardiance Empagliflozin Brand 88 $76,796
Tresiba Flextouch U-200 Insulin Degludec Brand 41 $54,994
Xarelto Rivaroxaban Brand 53 $47,488
Januvia Sitagliptin Phosphate Brand 33 $34,558
Trulicity Dulaglutide Brand 30 $33,738
Farxiga Dapagliflozin Propanediol Brand 32 $31,709
Linzess Linaclotide Brand 35 $28,582

The 10 drugs with the highest cost, of 176 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$3,414

Medicare's payments for the services billed

Medicare patients

27

Average age 69

Services billed

57

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

155 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record